Did you know? Hybrid AF™ Therapy with the EPi-Sense System is the first and ONLY FDA-approved device for minimally invasive ablation therapy to treat long-standing persistent Afib—the most prevalent and undertreated Afib patient population.
Visit us at <a href='https://www.linkedin.com/feed/hashtag/?keywords=APHRS&highlightedUpdate…; target='_blank'>#APHRS</a> to explore the latest clinical science and discover novel strategies for the treatment of Afib with Hybrid AF™ Therapies.
Learn more about Hybrid AF™ Therapy: <a href="https://okt.to/ib6A0W" target="_blank">https://okt.to/ib6A0W</a>
<a href='https://www.linkedin.com/feed/hashtag/?keywords=APHRS2024&highlightedUp…; target='_blank'>#APHRS2024</a> <a href='https://www.linkedin.com/feed/hashtag/?keywords=HybridAFTherapy&highlig…; target='_blank'>#HybridAFTherapy</a>
- Healthcare Professionals
- Therapies and Procedures
- Concomitant Surgical Ablation Therapy
- Ablation Sensing Unit & Switch Matrix
- cryoFORM® Cryoablation Probe
- cryoICE® BOX V6
- cryoICE® Cryoablation Probes
- Isolator® Linear Pen
- Isolator® Synergy™ Access® Clamp
- Isolator® Synergy™ Clamps (OLL2/OSL2)
- Isolator® Transpolar Pen (MAX3)
- Isolator® Synergy™ EnCompass® Clamp
- Multifunctional Ablation Generator (MAG)
- Hybrid AF™ Therapy
- Hybrid Total Thoracoscopic Therapy
- Left Atrial Appendage Management
- Cryo Nerve Block Therapy
- Concomitant Surgical Ablation Therapy
- Education & Training
- Clinical Evidence
- Product Labeling
- Resources
- Society Guidelines
- Therapies and Procedures
- Patients & Caregivers
- About AtriCure
